Unicycive Therapeutics Inc — Quarterly Cash Flow (NASDAQ:UNCY) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 31.67 M27.95 M30 M50.61 M49.13 M Total liabilities 24.24 M16.68 M13.57 M13.13 M18.94 M Total equity 7.43 M11.27 M16.43 M37.48 M30.2 M Total liabilities & shareholders' equities 31.67 M27.95 M30 M50.61 M49.13 M Total debt ————— Net debt —————

News

Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile

FDA sets June 27 review date for Unicycive’s kidney drug

Unicycive stock rises after FDA accepts OLC drug application resubmission

Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission

Unicycive resubmits NDA for kidney disease treatment to FDA

Piper Sandler highlights commercial biotech names to own in 2026

Unicycive stock price target lowered to $63 by Lucid Capital Markets

Unicycive to resubmit FDA application for kidney drug by year-end

Unicycive Therapeutics faces securities class action lawsuit over public statements

Unicycive receives U.S. patent for chronic kidney disease treatment

Unicycive Therapeutics: Manageable CMC Speed Bump - Pill Burden Edge Intact, Buying (UNCY)

Unicycive regains Nasdaq compliance after reverse stock split